UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 30,059 Shares of Veracyte, Inc. (NASDAQ:VCYT)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 20.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 174,463 shares of the biotechnology company's stock after buying an additional 30,059 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.23% of Veracyte worth $6,909,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of VCYT. Jones Financial Companies Lllp increased its holdings in Veracyte by 49.7% in the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 237 shares in the last quarter. US Bancorp DE increased its stake in shares of Veracyte by 57.4% in the fourth quarter. US Bancorp DE now owns 1,774 shares of the biotechnology company's stock valued at $70,000 after buying an additional 647 shares during the period. Principal Securities Inc. raised its holdings in Veracyte by 34.1% in the 4th quarter. Principal Securities Inc. now owns 1,909 shares of the biotechnology company's stock valued at $76,000 after buying an additional 485 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in Veracyte during the 4th quarter worth approximately $91,000. Finally, Sterling Capital Management LLC lifted its holdings in shares of Veracyte by 810.2% during the fourth quarter. Sterling Capital Management LLC now owns 2,421 shares of the biotechnology company's stock worth $96,000 after purchasing an additional 2,155 shares during the period.

Analyst Ratings Changes

Several research analysts have commented on VCYT shares. Stephens reaffirmed an "overweight" rating and set a $45.00 target price on shares of Veracyte in a report on Wednesday, March 26th. Needham & Company LLC reduced their target price on Veracyte from $51.00 to $41.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Wall Street Zen lowered shares of Veracyte from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Craig Hallum started coverage on shares of Veracyte in a research note on Thursday, March 20th. They issued a "buy" rating and a $45.00 price objective on the stock. Finally, UBS Group decreased their price objective on shares of Veracyte from $49.00 to $42.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Veracyte has an average rating of "Moderate Buy" and a consensus price target of $40.90.

Veracyte Price Performance

Shares of VCYT stock traded up $0.07 on Thursday, reaching $27.36. 164,056 shares of the company were exchanged, compared to its average volume of 900,256. Veracyte, Inc. has a one year low of $19.73 and a one year high of $47.32. The company has a 50-day moving average of $29.78 and a 200-day moving average of $36.20. The company has a market cap of $2.14 billion, a price-to-earnings ratio of -181.47 and a beta of 2.14.

Veracyte Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.